CONICET | Buscador de Institutos y Recursos Humanos

Therapeutic and diagnostic methodologies based in nanotechnology are ofimportance nowadays. These protocols are meant be less invasive, more efficientand displaying minor side effects, being endowed of selectivity. Magnetichyperthermia (MH), a modality that uses radio-frequency (RF) magnetic fields toheat single-domain magnetic nanoparticles (NPs), is becoming a powerfuloncological therapy. Iron oxide NPs are the most biocompatible materialsaccepted as a medical device. MH has reached clinical trial, but there are stillunsolved problems like: dosage; NPs spatial distribution in target tissue andtemperature distribution, monitoring and increase control. Dosage is mainlydetermined by NPs´s efficiency to transduce heat (SAR).This efficiency dependson magnetic relaxation and it is highly influenced by NP size, aggregation andinteraction. It is further modified by restricted mobility and confinement insidetumour environment. We have performed MH experiments in ferrofluids [1,2], invitro [3] and more recently in vivo mice assays. We have analyzed aqueousdispersion of single NPs and randomly or magnetically organized multicore. Weproved that the relevant physical parameters for predicting fluid SAR are meanNP volume, its saturation magnetization and a representative mean activationenergy, and that SAR depends on concentration [2,4]. In vitro experiments wereused to determine uptake, distribution, cytotoxicity and to develop a newmethodology for probing intracellular heating in cells cultures [3]. In vivoconstitute a more complex scenario because after intratumoral infiltrationirregular NP distribution patterns occurs.Also we will present a new portable device, optimized to generate fields of 100kHz and amplitude from 2 to 15 kA/m, versatile for MH research in materials, cellcultures and mice models.[5].[1] 10.1021/jp311556b[2] 10.1021/acs.langmuir.5b03559[3] 10.1021/acs.jpcc.5b12330[4] 10.1039/c6cp08059f[5] Patent Nº 20160101254